Bayer U.S. Rx Headed By Foster During Transition; BI U.S. CEO-Elect Is Carroll
Bayer diagnostics exec Colin Foster is overseeing U.S. pharmaceuticals while the company resolves its future participation in the Rx drug sector
You may also be interested in...
Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12
Boehringer Ingelheim/Pfizer's Spiriva demonstrates a clinically meaningful bronchodilator effect when used to treat chronic COPD patients, FDA's Pulmonary-Allergy Drugs Advisory Committee unanimously agreed Sept. 6
Bayer is in discussions with smaller specialty pharmaceutical companies over potential partnerships as it looks to build up its drug business